Cargando…
P944: REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK
Autores principales: | Spicka, Ivan, Lapidot, Ido, Merz, Maximilian, Radocha, Jakub, Stork, Martin, Jelínek, Tomas, Jungova, Alexandra, Minarik, Jiri, Soukup, Jan, Van Speybroeck, Michel, Perualila, Nolen, Diels, Joris, Duarte Mendes, João, van Nimwegen, Kirsten, Strobel, Kai, Wischlen, Sebastien, Sliwka, Henrik, Gros Otero, Blanca, Hajek, Roman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431474/ http://dx.doi.org/10.1097/01.HS9.0000970680.25812.6d |
Ejemplares similares
-
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
por: Stork, Martin, et al.
Publicado: (2023) -
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
por: Minarik, Jiri, et al.
Publicado: (2021) -
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy
por: Minarik, Jiri, et al.
Publicado: (2022) -
Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017) -
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)